Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Argenx Se ( (ARGX) ) has provided an update.
On June 30, 2025, argenx SE announced the advancement of ARGX-119, a first-in-class agonist antibody targeting muscle-specific kinase (MuSK), to a registrational study for congenital myasthenic syndromes (CMS). This decision follows positive results from a Phase 1b study, which demonstrated a favorable safety profile and consistent functional improvement across multiple efficacy measures. The advancement of ARGX-119 underscores the strength of argenx’s Immunology Innovation Program and its commitment to addressing unmet needs in neuromuscular diseases. The study’s results are expected to impact the company’s operations positively by further validating its innovative approach and potentially improving its industry positioning.
The most recent analyst rating on (ARGX) stock is a Buy with a $721.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Neutral.
Argenx Se’s strong financial performance, highlighted by impressive revenue growth and a robust earnings call, boosts its overall score. However, mixed technical indicators and valuation challenges slightly temper the outlook.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
argenx is a global immunology company focused on developing novel antibody-based medicines to treat severe autoimmune diseases. The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a world-class portfolio of medicines. Argenx has developed and commercialized the first approved neonatal Fc receptor (FcRn) blocker and is advancing several experimental medicines within its therapeutic franchises.
Average Trading Volume: 409,732
Technical Sentiment Signal: Buy
Current Market Cap: $34.31B
For detailed information about ARGX stock, go to TipRanks’ Stock Analysis page.